Programme

SPEAKERS

Hideyuki Saya

AFFILIATION:

Fujita Health University, Aichi, Japan

POSITION TITLE:

Director and Professor, Fujita Cancer Center
Emeritus Professor, Keio University, Tokyo, Japan

EDUCATION/TRAINING:

Kobe University School of Medicine, Kobe, Japan, Ph.D., 1987, Immunology

Kobe University School of Medicine, Kobe, Japan, M.D., 1981, Medicine

Post-Doc, Brain Tumor Research Center, University of California, San Francisco, Jan. 1987-Jun 1988

HONORS:

The 6th Special Research Award, Sagawa Foundation for Promotion of Cancer Research, 2008

The 29th Yoshida Prize, Japanese Cancer Association, 2020

                              Fukuzawa Prize, Keio University, 2020

RESEARCH INTERESTS:

Active

Project for Elucidating and Controlling Mechanisms of Aging and Longevity, Japan Agency for Medical Research and Development (AMED)

Co-investigator

 “Elucidation of mechanisms regulating aging of intestinal tract by stromal cells”, 10/01/2017-03/31/2022, 10,000,000 yen/yr (approximately $100,000/yr), 10% effort

Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan  

Principle Investigator

“Elucidation of induction mechanism of cancer-associated fibroblasts by MKL1 transcriptional regulator and its clinical applications”, 04/01/2017-03/31/2023, 14,000,000 yen/yr (approximately $140,000/yr), 10% effort

 

Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)

Principle Investigator

“Development of cancer stem cell targeting therapy by using polyethylene glycol-conjugated sulfasalazine (PEG-SSZ) based on DDS technology”, 04/01/2017-03/31/2020, 36,250,000 yen/yr (approximately $360,000/yr), 10% effort

Completed (2007-2020)

Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)

Principle Investigator

“Development of cancer stem cell targeting therapy by using polyethylene glycol-conjugated sulfasalazine (PEG-SSZ) based on DDS technology”, 04/01/2017-03/31/2020, 36,250,000 yen/yr (approximately $360,000/yr), 10% effort

Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan  

Principle Investigator

“Development of new therapeutic strategies to suppress invasiveness of glioblastoma by targeting the invasive complex composed by glioma stem cells and endothelial cells”, 04/01/2013-03/31/2016, 12,000,000 yen/yr (approximately $120,000/yr), 10% effort

Next-generation Cancer Research Strategy Promotion Project, The Ministry of Education, Culture, Sports, Science and Technology, Japan

Principle Investigator

“Development of drugs inducing transdifferentiation by regulating transcription factors based on actin dynamics”, 10/01/2014-03/31/2016, 20,000,000 yen/yr (approximately $210,000/yr), 20% effort

Translational Research Network Program, The Ministry of Education, Culture, Sports, Science and Technology, Japan

Principle Investigator

“Phase I investigator-initiated clinical trial evaluating first-line treatment with sulfasalazine plus pemetrexed and cisplatin, which targets cancer stem cells in progressive non-squamous non-small cell lung cancers”, 04/01/2014-03/31/2017, 30,000,000 yen/yr (approximately $320,000/yr), 20% effort

Grant-in-Aid for Scientific Research on Innovative Areas "Cancer Stem Cells" of The Ministry of Education, Culture, Sports, Science, and Technology, Japan.    

Principle Investigator

“Development of strategies for drug resistance of cancer stem cells”, 04/01/2010-03/31/2015, 31,000,000 yen/yr (approximately $330,000/yr), 20% effort

Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan  

Principle Investigator

“Development of new therapeutic strategies to overcome drug resistance and invasiveness of glioblastoma by using mouse brain tumor models based on cancer stem cells”, 04/01/2010-03/31/2013, 15,900,000 yen/yr (approximately $160,000/yr), 10% effort

Grant from Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency (JST)

Principle Investigator

“Analysis of abnormal regulation of cell differentiation and drug development research by using induced cancer stem cells”, 06/01/2008-03/31/2014, 70,000,000 yen/yr (approximately $730,000/yr), 60% effort

Grant for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan       Principle Investigator

“Screening of inhibitors for cancer invasion and metastasis by using the EMT visualizing system”, 04/01/2010-03/31/2011, 3,100,000 yen/yr (approximately $32,000/yr), 5% effort

Grant for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan       Principle Investigator

“Impairment of mitotic regulation and its role in carcinogenesis”, 04/01/2005-03/31/2010, 25,000,000 yen/yr (approximately $220,000/yr), 20% effort

Grant for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan Cancer Research Grant from the Ministry of Education, Science and Culture of Japan       Principle Investigator

“Development of new molecular therapeutic approaches for malignant brain tumors”, 04/01/2007-03/31/2009, 20,000,000 yen/yr (approximately $180,000/yr), 15% effort

Grant from Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), Japan    Co-Investigator

“Development of drugs for cancer invasion and metastasis”, 04/01/2007-03/31/2010, 16,000,000 yen/yr (approximately $160,000/yr), 5% effort

PUBLICATIONS:

https://www.scopus.com/authid/detail.uri?authorId=7007113088